Inspire Investing’s Starling Oncology STLN Stock Holding History

Inspire Investing’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-424,008	Closed	-$2.3M	–	1385
2026 Q2	$2.3M	Buy	+424,008	New	+$1.78M	0.09%	248

Other funds holding STLN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Mount Lucas Management Newtown, Pennsylvania $333M AUM 24.96% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Kingswood Wealth Advisors San Diego, California $2.6B AUM 27.46% 1-Year Est. Return

Inspire Investing's STLN Position: Q3 2026 in Review

Inspire Investing sold out of Starling Oncology (STLN) in Q3 2026, closing a stake of 424,008 shares — an estimated $2.3M sold.

Inspire Investing first reported a position in STLN in Q2 2026 and held it in 1 quarter. The position peaked at $2.3M in Q2 2026. 55 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

Inspire Investing reported no remaining Starling Oncology position as of Q3 2026 after selling out during the quarter.
Inspire Investing sold 424,008 Starling Oncology shares in Q3 2026, an estimated $2.3M.
Inspire Investing first reported a position in Starling Oncology in Q2 2026 and held it in 1 quarter.
Inspire Investing's Starling Oncology position peaked at $2.3M in Q2 2026.
55 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on Inspire Investing's 13F filing for Q3 2026, filed 22 Oct 2026.